anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: An anti-inflammatory composition containing Rhus succedanea extract is provided to suppress NO generation and inducible NOS expression and ensure anti-inflammation effect without side effects. CONSTITUTION: A pharmaceutical composition for anti-inflammation contains Rhus succedanea extract as an active ingredient. The Rhus succedanea extract is obtained using water, alcohol or their mixture. The alcohol is C1-C4 low alcohol. A method for producing the Rhus succedanea extract comprises: a step of pulverizing the Rhus succedanea and adding extraction solvent; a step of filtering the extract; and a step of decompressing and freeze-drying. The skin external formulation for anti-inflammation contains the Rhus succedanea extract an active ingredient.
BACKGROUND: Neuroinflammation is a vital pathogenic mechanism for neurodegenerative diseases such as Alzheimer's, schizophrenia, and age-related cognitive decline. Regulatory T cells (Tregs) exhibit potent anti-inflammatory properties and can modulate neurodegenerative diseases arising from central nervous system inflammatory responses. However, the role of Tregs in neuroinflammation-related cognitive dysfunction remains unclear. It is highly plausible that Htr7+ Tregs expressing unique genes associated with the nervous system, including the Htr7 gene encoding the serotonin receptor 5-HT7, play a pivotal role.
METHODS: Mice were given a tryptophan-rich diet (with a tryptophan content of 0.6%) or a normal diet (with a tryptophan content of 0.16%). The neuroinflammation-mediated cognitive dysfunction model was established by intracerebroventricular injection of lipopolysaccharide (LPS) in 8-week-old C57BL/6J mice. The activation and infiltration of Tregs were measured using flow cytometry. Primary Tregs were cocultured separately with primary CD8+ T cells and primary microglia for in vitro validation of the impact of 5-HT and 5-HT7 receptor on Tregs. Prior to their transfer into recombination activating gene 1 (Rag1-/-) mice, Tregs were ex vivo transfected with lentivirus to knock down the expression of Htr7.
RESULTS: In this study, the tryptophan-rich diet was found to reverse LPS-induced cognitive impairment and reduce the levels of 5-HT in peripheral blood. The tryptophan-rich diet led to increased levels of 5-HT in peripheral blood, which in turn promoted the proliferation and activation of Htr7+ Tregs. Additionally, the tryptophan-rich diet was also shown to attenuate LPS-mediated neuroinflammation by activating Htr7+ Tregs. Furthermore, 5-HT and 5-HT7 receptor were found to enhance the immunosuppressive effect of Tregs on CD8+ T cells and microglia. In Rag1-/- mice, Htr7+ Tregs were shown to alleviate LPS-induced neuroinflammation and cognitive impairment.
CONCLUSIONS: Our research revealed the ability of Htr7+ Tregs to mitigate neuroinflammation and prevent neuronal damage by suppressing the infiltration of CD8+ T cells into the brain and excessive activation of microglia, thereby ameliorating LPS-induced cognitive impairment. These insights may offer novel therapeutic targets involving Tregs for neuroinflammation and cognitive impairment.
<P>PROBLEM TO BE SOLVED: To provide a sheet brush for hair which can improve convenience as a brush for conditioning and mending hair by using projections to permit easy combing of the hair.  <P>SOLUTION: The sheet brush 10 for hair is dispersedly arranged with a plurality of the projections on one surface of a substrate sheet 11, in which the respective projections 12 have elliptic flat sectional shapes having a major axis X and a minor axis Y, are decreased in their sectional areas toward their front ends, and are respectively protruded to conical shapes. A plurality of the projections 12 are dispersedly arranged on one surface of the substrate sheet 11 by paralleling their major X directions with each other. The substrate sheet 11 consists of a nonwoven fabric and a plurality of the projections 12 are disposed to project portions of the substrate sheet 11. The sheet brush for hair is used by being impregnated with various kinds of cosmetics for hair, such as odor eliminating bases, deodorant bases, water absorptive bases, antimicrobial agents, and UV absorbents.  <P>COPYRIGHT: (C)2003,JPO
In Arm A, patients with refractory relapse receive a 2 week treatment with MabCampath followed by remission evaluation. In case of insufficient response, treatment with cladribine is added.
Psoriasis, a chronic inflammatory skin disorder, is associated with comorbidities such as acute myocardial infarction (AMI). However, the molecular mechanisms connecting these conditions are unclear. In this study, we conducted bioinformatics analyses using gene expression datasets to identify differentially expressed genes and hub genes associated with both psoriasis and AMI. Our findings emphasize the involvement of immune-related pathways in the pathogenesis of both conditions. Furthermore, we investigated the expression levels of hub genes in AMI patients and myocardial infarction (MI) mice. ELISA measurements revealed significantly higher levels of CXCL8, IL1B, S100A9, and S100A12 in the serum of AMI patients compared to normal individuals. Immunohistochemical staining of heart tissue from MI mice showed a progressive increase in the expression of CXCL8 and IL-1B as MI advanced, while S100A9 exhibited high expression at day 3 post-MI. mRNA expression analysis validated these findings. Additionally, we explored the skin lesions of psoriasis patients and found significantly higher expression of CXCL8, IL-1B, S100A9, and S100A12 in the affected skin areas compared to unaffected regions. These results highlight the consistent upregulation of hub genes in both AMI and psoriasis patients, as well as in myocardial infarction mice, underscoring their potential as reliable markers for disease diagnosis. Moreover, molecular docking simulations revealed potential interactions between simvastatin and key target proteins, suggesting a potential therapeutic avenue. Overall, our study uncovers shared molecular signatures and potential therapeutic targets, providing a foundation for future investigations targeting common pathways in psoriasis and AMI.
H-Y is a transplantation antigen that can lead to rejection of HLA-matched male organ and bone marrow grafts by female recipients, and may play a role in pregnancy and spermatogenesis. However, the origin and function of H-Y  antigens has eluded researchers for 40 years. We show that one human H-Y  peptide antigen presented by HLA-B7 is an 11 residue peptide derived from SMCY, an evolutionarily conserved Y chromosomal protein. A homologous gene on the X chromosome, SMCX, differs by two residues in the same region. We also show a peptide antigen recognized by two HLA-A2.1 restricted T cell clones, which is also encoded by SMCY. The identification of H-Y offers prospects for improvements in transplantation outcome, prenatal diagnosis and fertilization strategies.
Apolipoprotein E-knockout (Apoe-/-) mice constitute the most widely employed animal model of atherosclerosis. Deletion of Apoe induces profound hypercholesterolemia and promotes the development of atherosclerosis. However, despite its widespread use, the Apoe-/- mouse model remains incompletely characterized, especially at late time points and advanced disease stages. Thus, it is unclear how late atherosclerotic plaques compare to earlier ones in terms of lipid deposition, calcification, macrophage accumulation, smooth muscle cell presence, or plaque necrosis. Additionally, it is unknown how cardiac function and hemodynamic parameters are affected at late disease stages. Here, we used a comprehensive analysis based on histology, fluorescence microscopy, and Doppler ultrasonography to show that in normal chow diet-fed Apoe-/- mice, atherosclerotic lesions at the level of the aortic valve evolve from a more cellular macrophage-rich phenotype at 26 weeks to an acellular, lipid-rich, and more necrotic phenotype at 52 weeks of age, also marked by enhanced lipid deposition and calcification. Coronary artery atherosclerotic lesions are sparse at 26 weeks but ubiquitous and extensive at 52 weeks; yet, left ventricular function was not significantly affected. These findings demonstrate that atherosclerosis in Apoe-/- mice is a highly dynamic process, with atherosclerotic plaques evolving over time. At late disease stages, histopathological characteristics of increased plaque vulnerability predominate in combination with frequent and extensive coronary artery lesions, which nevertheless may not necessarily result in impaired cardiac function.
Patients will receive combined trametinib and ribociclib based on evidence to suggest that combined MEK inhibition and CDK4/6 inhibition may be effective. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.
The invention provides assays for the presence or absence of CD4+ T cell subpopulations carrying particular V beta  components of the T cell receptor (TCR-V beta ) in persons infected with HIV, including amplification of mRNA from T cells with primers specific to each TCR-V beta  to detect the presence or absence of each TCR-V beta  in a sample and primers for use in such amplification assays are disclosed. The invention also provides assays of antibody-containing fluids of a person infected with HIV to determine the immunodeficiency where the fluid is suspected to contain an antibody having a paratope specific to an epitope on a TCR-V beta . The invention also provides a binding agent specific to a paratope where the paratope is specific to an epitope on a TCR-V beta . The invention also provides a method of assay of the fluids of a person infected with HIV to determine the immunodeficiency of the person which utilizes a binding agent specific to complexes containing anti-TCR-V beta  antibody bound to TCR-V beta . The invention also provides a method of treatment of a person infected with HIV to attenuate or avert immunodeficiency which utilize a binding agent that is homologous with an epitope on TCR-V beta . The invention also provides a method of treatment of a person infected with HIV to attenuate or avert immunodeficiency which involves removing an antibody capable of binding to an epitope on TCR-V beta  from the blood of a person infected with HIV. Finally, the invention provides a method of vaccination of a person infected or at risk for infection with HIV which raises antiidiotypic antibodies specific to free antibodies containing a paratope specific to an epitope on a TCR-V beta .
This study is a multi-center, randomized, open-label, controlled trial. Eligible patients will be randomized to neoadjuvant pyrotinib or pertuzumab containing regimen every 3 weeks for four cycles before surgery. Randomization was stratified by the following factors: hormone receptor status and primary tumor size. After completing four cycles of neoadjuvant treatment, all patients who are eligible for surgery will undergo surgery and have their pathologic response evaluated. Following surgery, patients will receive 90-100 mg/m2 epirubicin and 600 mg/m2 cyclophosphamide every 3 weeks for 4 cycles. Clinicians will select subsequent treatments for patients based on guidelines as well as clinical practice at each site.
PROBLEM TO BE SOLVED: To provide a system and a method that calculate an athletic activity parameter.SOLUTION: A plurality of housings 404 is disposed at a plurality of portions on a body of a user. The plurality of housings is configured so as to detachably fit to an electronic module 402. The electronic module is provided with sensors 420, 422 and 424, and a processor. The processor is configured so as to calculate an athletic activity parameter. Each housing is connected to an ID memory 412 or is provided with an ID memory. The ID memory stores information identifying a location of the housing. The electronic module uses location information for selecting an algorithm for use in calculation of the athletic activity parameter.
PURPOSE:To provide an oral medicinal preparation useful as a treating and preventing agent for cardiac diseases, capable of being simply and economically prepared and stable for a long period by adding mannitol and polyethylene glycol to bisoprolol or a salt thereof. CONSTITUTION:An oral medicinal preparation stable for a long period comprises 1-30wt.%, especially approximately 2-20wt.% of bisoprolol or a salt thereof, 50-90wt.% of mannitol, and 5-30wt.% of polyethylene glycol. The polyethylene glycol has an average mol.wt. of 1000-2000, preferably 4000-6000. The preparation, especially the tablets, do not require a disintegrator due to the extremely rapid elution of the main ingredient to digestive tract. The agent has such advantages that the bisoprolol serves for the preparation as a binder.
Hernioplasty stands as one of the most common abdominal surgical interventions. The "gold standard" treatment for inguinal hernias remains Lichtenstein mesh hernioplasty. Nonetheless, clinical practice continues to grapple with issues concerning complications such as recurrence, chronic postoperative pain, and infection. The myriad types of surgery lead to conflicting opinions regarding the superiority and drawbacks of inguinal canal plastic surgery methods. This article presents current data on the surgical treatment of non-mesh inguinal hernias, delineating the most prevalent techniques while exploring their respective advantages and disadvantages. Additionally, the researchers' experiences are analyzed in detail.
Systems and methods of tumor segmentation are receiving data having dimensions of a first size and a first kernel size. A residual volume is produced from the input volume. A first, second, and third intermediate volume are produced by from convolving a first, second, and third dimension volume of the residual volume to 1. A first global volume is produced from sums of the residual volumes. A downsampled volume is produced from the input volume. A residual downsampled volume is produced from the downsampled volume. A first, second, and third intermediate downsampled volume is produced from convolving a first, second, and third dimension volume of the downsampled volume to 1. A second global volume is produced from sums of the intermediate downsampled volumes. The second global volume is upsampled. An output volume is produced from integrating the first global volume and the second global volume.
The invention provides a preparation method of a triple inactivated vaccine for pigs. The method determines an antigen composition with excellent immunization effects by selection of the antigen. The prepared polyvalent vaccine has outstanding immunization effects. The prepared vaccine contains a PCP immunization protective antigen exotoxin (Aps), has cross immunization protection effects better than those of a whole cell inactivated vaccine, greatly reduces side reaction, and can simultaneously prevent haemophilus parasuis, swine streptococcosis and actinobacillus pleuropneumonia by combined immunization with inactivated haemophilus parasuis and streptococcus suis. Compared with haemophilus parasuis and streptococcus suis inactivated vaccines sold on the market, the triple inactivated vaccine has the same corresponding pathogen immune protection force. Compared with the actinobacillus pleuropneumonia inactivated vaccine sold on the market, the triple inactivated vaccine has a cross immunization protecting force on diseased pigs with different serotypes and realizes multiple protection purposes.
Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK) 2  (ARARADAD) 2 , were shown to self-assemble into macroscopic membranes. Conditions under which the peptides self-assemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic. The membranes are potentially useful in biomaterial applications such as slow-diffusion drug delivery systems, artificial skin, and separation matrices, and as experimental models for Alzheimer's disease and scrapie infection. The sequence of the peptide, EAK16, was derived from a putative Z-DNA binding protein from yeast, called zuotin. The cloning and characterization of the ZUO1 gene are also described.
Background: Neonatal hypothermia is a major cause of preventable morbidity and mortality, especially among the world's poorest newborns. A heat-producing wrap is necessary when kangaroo mother care (KMC) is insufficient or unavailable, yet there is little published research on such wraps. The Dream Warmer is a wrap designed to complement KMC and has been extensively studied in formal research settings but not in real-world conditions. Objectives: We used implementation science methodology to understand the safety, effectiveness, and functionality of the Dream Warmer (hereafter, "Warmer"); its effect on clinical workflows; its interaction with other aspects of care such as KMC; and the Warmer's reception by healthcare providers (HCPs) and parents. Methods: We conducted a prospective, interventional, one-arm, open-label, mixed-methods study in 6 district hospitals and 84 associated health centers in rural Rwanda. Our intervention was the provision of the Warmer and an educational curriculum on thermoregulation. We compared pre and post intervention data using medical records, audits, and surveys. Findings: The Warmer raised no safety concerns. It was used correctly in the vast majority of cases. The mean admission temperature rose from slightly hypothermic (36.41 °C) pre, to euthermic (36.53 °C) post intervention (p = 0.002). Patients achieved a temperature ≥36.5 °C in 86% of uses. In 1% of audits, patients were hyperthermic (37.6-37.9 °C). Both HCPs and parents reported a generally positive experience with the Warmer. HCPs were challenged to prepare it in advance of need. Conclusions: The Warmer functions similarly well in research and real-world conditions. Ongoing education directed toward both HCPs and parents is critical to ensuring the provision of a continuous heat chain. Engaging families in thermoregulation could ease the burden of overtaxed HCPs and improve the skill set of parents. Hypothermia is a preventable condition that must be addressed to optimize neonatal survival and outcome.
Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose during TP (1 to 3) with planned escalated doses as 3 mg, 20 mg and 45 mg. Dose of 3 mg will be given as solution and that of 20 and 45 mg, as capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive 60 microgram per meter\^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
The invention belongs to the field of medicine preparation, and in particular relates to application of inosine in preparing a medicine for preventing decompression sickness caused by fast buoyancy ascent escape. The inosine is dissolved in normal saline, so that an injection with concentration ranging from 25mg/mL to 125mg/mL is prepared for use. For intraperitoneal injection, the dosage of the inosine is 50-250mg/kg. The inosine is applied 25-35min before the fast buoyancy ascent escape. Upon experiments, the inosine can significantly relieve lung injury and inflammation, so that pathologic change caused by the decompression sickness is relieved and lung functions are improved; and the inosine can inhibit heart failure caused by edema and breakage of cardiac muscle fibers due to the existence of bubbles. Moreover, the invention provides experimental data for the more reasonable application of the inosine to the prevention of decompression sickness caused by fast buoyancy ascent escape in the clinical field.
Premature birth, i.e. the birth of babies before the 37th week of pregnancy, is an increasing challenge. Since the 1980s, medical advances such as special medication and ventilation techniques have significantly improved the chances of survival for premature babies. Worldwide, around 11% of all births are premature. Prematurity increases the risk of cardiovascular disease. Studies show that very premature babies have a significantly higher risk of heart problems. However, only little is known whether physical exercise could improve cardiovascular and cognitive function in prematurely born children.

All participants will undergo a baseline visit to assess vascular, cognitive and cardiopulmonary function. At the end of the visit, participants will be randomly allocated to either an intervention group or a control group. The intervention will receive a child-friendly physical exercise program and the control group will receive age appropriate lifestyle- and exercise recommendations. The physical exercise program is held 2-3 times per week for ten weeks targeting cardiovascular health and coordination. After 10 weeks, all participants will undergo a follow-up visit at which all measures will be repeated.
The present invention discloses a Chinese herbal medicinal immune intensifier prepared from left-eyed flounders and right-eyed flounders. The present invention is characterized in that the present invention is prepared from constituents of the following share by weight: 90 to 110 of ginseng, 115 to 135 of honeysuckle flower, 115 to 135 of spine date seed, 115 to 135 of garlic, 115 to 135 of haw and 90 to 110 of schisandra. The constituents interact, the present invention has nutrition property as well as medicine property, namely that the present invention not only contains nutritive substances, but also has antibacterial activity and ingredients with other biological activity. The present invention can improve the basic metabolism of fish, promote growth and development, enhance the immunological function, prevent diseases, etc. The present invention not only overcomes harm caused by chemical disinfectant and bacteriophage of the prior art to a human body, but also solves the problems of the existing marine product vaccine, such as strong specificity and high cost. The present invention has the advantages of wide source of raw materials, low price and convenient use, and the present invention has higher social benefits and economic benefits.
NEW MATERIAL:A neutral saccharide-containing luteinized hormone containing >=18% of the neutral saccharide chain component in the saccharide chain component composition of the beta-subunit thereof. USE:A kidney growth-accelerating agent. PREPARATION:For example, a swine pituitary is homogenized in an ammonium sulfate aqueous solution, adjusted to a pH of 3.0 and centrifuged to collect a supernatant solution, which is adjusted to a pH of 6.5-7.0, mixed with ammonium sulfate to become 0.5 saturation, cooled and centrifuged. The resultant precipitates are collected, suspended in a buffer solution, dialyzed and subsequently lyophilized. The lyophilized powder is dissolved in a buffer solutions and fractionated with ConA-sepharose column to collect a fraction eluted with 0.2M methylmannoside. The fraction is purified with a column for isoelectric point electrophoresis to provide a kidney growth factor.